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INTRODUCTION
The value of postoperative radiotherapy in
patients with operable breast cancer has been a
subject of a long lasting controversy. This
modality was found to be very effective in
preventing locoregional recurrences but its
impact on the survival has been unclear. Recent
metaanalises of clinical triais have indicated that
radiotherapy may improve survival in some
patients, but it mayaiso increase non breast
cancer mortality (Cuzick et al., 1994, Cuzick,
1987; EBCTCG, 1995).
In postmastectomy irradiation the treatment
volume is large and irregular and it includes the
chest wall and regional Iymph nodes: internal
mammary, supraclavicular and apex of the
axilla. Within this volume there are several
organs and tissues which may potentially be
damaged by radiation: the skin and
subcutaneous tissue, ribs and clavicle,
Iymphatic vessels, brachial plexus and the
shoulder joint. The lung and heart are in direct
proximity to the treatment volume and,
depending on radiotherapy technique, these
organs mayaiso receive significant doses.
There are several methodological problems in
assessing the risk of late side effects and
complications. In the first place, it is very difficult
to estimate the incidence of sequelae in
retrospective analysis with the exception of very
severe complications which require treatment,
and hospitalisation or are lethal. The real
incidence of mild or asymptomatic effects can
only be estimated, if a prospective protocol is
implemented and carefully folIowed. This should
include assessment and scaling the effects at
regular intervals and performing additional
studies, if necessary, e.g. chest X-ray to
document radiation changes in the lung or
asymptomatic rib fracture. Secondly, all of the
late radiation effects show the existence of the
latent period when both the incidence and
severity tend to increase with time. Some
patients die from the metastatic disease shortly
after the treatment, in others follow-up is not
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long enough to cover the latency period of a
particular complication. Thus, the incidence of
late radiation changes should be calculated only
with the actuarial methods. Thirdly, there are
some complications, like induced secondary
cancers or radiation-related heart disease,
which may be difficult to separate from those
occuring in the absence of radiotherapy. The
risk of these complications requires evaluation
either by using randomised cHnical triais
involving the control group not treated with
irradiation, or by employing epidemiological
techniques within a large population-based
registry (Bentzen and Overgaard, 1994;
Bentzen, 1993; Turreson, 1989).
The aim of this presentation is to review the
current knowledge concerning the late radiation
effects and complications in breast cancer
patients with special emphasis on radiation
induced heart deaths and secondary
neoplasms.
TYPE OF LATE RADlATlON EFFECTS AND
COMPLlCATIONS OCCURRING IN BREAST
CANCER PATIENTS AND FACTORS
INFLUENCING THE RISK
1. Possible late sequelae and complications of
postmastectomy radiotherapy in breast
cancer patients include: teleangiectasia,
subcutaneous fibrosis, soft tissue necrosis,
arm oedema, brachial plexopathy, impaired
shoulder movement, rib fractLlre, lung
fibrosis, radiation related heart disease, and
carcinogenesis (Table 1).
2. Factors that may influence the incidence
and severity of these effects include:
radiation therapy factors (dose, dose
distribution within the treated volume, and
the fraction size), interaction with other
treatment modalities (Le. surgery and
chemotherapy), and individual
radiosensitivity of the patients.
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Treatment volume Tissue and organs Possible late
in postmastectomy within high dose effects and
irradiation volumeorin complications
cIose proximity.
Chest wall skin and teleangiectasia
subcutaneous and fibrosis
tissue
ribs, clavicle bane necrosis
Lymph nodes:
-supraclavicular, Iymphatic vessels arm oedema











Table 1. Late side effects and complications in breast
cancer patients treated with postoperative
radiotherapy.
quality of radiation and technique are
also important in some situations. In
most of the effects the importance of the
dose per fraction was demonstrated in
clinical studies (Table 2). With the use
of large fractions a significant increase
in the incidence of late changes and
complications was found for the
following effects: teleangiectasia,
fibrasis, 50ft tissue necrosis, impaired
shoulder movement, rib fracture, lung
fibrasis, and brachial plexus damage. In
these effects, the low alfa/beta ratios
between 2-5 Gy, and latency periods
ranging fram 2-15 years were calculated
from c1inical data (Table 3), (Bentzen
and Overgaard; 1994, Bentzen; 1993,
Fletcher; 1991, Powell et al.; 1990).
Tissue Effect alp ratio LTgo
(Gy) (years)
subcutis fibrosis 1.9 3.2
vasculature teleangiectasia 2.8 2-15
lung fibrosis 3.6 ?
bane necrosis 3 <3
muscle "frozen shoulder" 3.5 3.9
/vasculature/
cartilage
nerve brachial <5.3 ?
plexopathy
Table 3. a/p ratios and latency period for late effects
after postmastectomy radiotherapy. Modified from SM
Bentzen (Bentzen, 1993).
Effect 36.5 Gy/12 42 Gy/22 p-value
fractions fractions
73 patients 66 patients
Teleangiectasia 29% 12% 0.009
grade ~ 2
Fibrosis 67% 5% <10-8
grade ~ 2
Lung fibrosis 32% 17% 0.04
grade ~ 2
Arm oedema 45% 33% 0.14
Rib fractures 19% 2% 0.0003
"Frozen 40% 11% 2x10 -8
shoulder"
grade ~ 2
Table 2. Incidence ot various late effects after twa
protocols for postmastectomy radiotherapy using
different doses per fraction. Modified from SM
Bentzen and M.Overgaard (Bentzen and Overgaard,
1994).
2.1. In generał the risk of late radiation
sequelae increases with the total dose.
Dose distribution associated with the
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2.2. Modern treatment of operable breast
cancer usually involves a combination of
surgery, radiotherapy, and systemic
adjuvant chem%r hormonal therapy.
There is some clinical evidence that
these modalities may have a combined
effect on the treatment-related
morbidity. The extent of the surgical
removal ofaxillary nodes is related to
the incidence of arm oedema which is
increased by radiotherapy. The extent of
tumour excision in the breast conserving
therapy influences the cosmetic effect,
an important endpoint in patients treated
with this method. Concomitant
application of radiation and
chemotherapy increases the incidence
of several radiotherapy related effects
such as arm oedema, subcutaneous
fibrasis, rib fracture, symptomatic
pneumonitis and poor cosmesis in
patients treated with breast conserving
therapy (Table 4-6), (Fowble; 1992;
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Harris and Morraw, 1996). The
interaction between radiation and
anthracyclines resulting in heart
damage is of special interest (Hju
Yiannakis and Yarnold, 1996).
Radiatian Incidence (%)
dose without CT withCT Total
:5.50 Gy 0.4% 3.7% 1.3%
p=0.002
>50Gy 3.2% 7.9% 5.6%
p=N.S. p=0.004
Total 0.6% 4.5% 1.8%
p<0.0001
Table 4. Incidence ot brachial plexopathy in relation to
radiation dose and use ot chemotherapy. Modified
from JR Harris and M Morrow (Harris and Morraw,
1996).
Radiation Incidence (%)
dose 4MV p Value 60r8 MV Total
:5.45 Gy 004 % 0% 0.2%
>45-<50 Gy 104% N.S. 0.8% 1.3%
~ 50 Gy 5.7% 0% 5.3%
Total 2.2% 0.05 0.4% 1.8%
Use ot CT
without CT withCT
:5.50 Gy 0.5% 2.3% p=0.01
>50% 4.7% 7.4% N.S.
Table 5. Incidence ot rib tracture in relation to
radiation quality, dose and use of chemotherapy (eT).
Modyfied fram JR Harris and M Morrow (Harris and
Morrow, 1996).




concurrent eT 8.8% 0.002
Table 6. Incidence of radiation pneumonitis in relation
to the use and seąuencing of chemotherapy. Modified
from JR Harris and M Morraw (Harris and Morrow,
1996).
2.3. Clinical observations have shown that
within a group of identically treated
patients there is a large variability in the
incidence and severity of radiation
sequelae in normaI tissues (Bentzen
and Overgaard, 1994; Turesson, 1990).
This variability may be explained only in
part by the random nature of celi killing
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by radiation and some predisposing
factors, including age, and a coexisting
disease, e.g. collagen vascular disease,
diabetes mellitus or infection. An
important factor contributing to this
phenomenon is a considerable
variability in intrinsic cellular
radiosensitivity fram individual to
individual which may be genetically
dependent. There are several genetic
syndrames associated with
hypersensitivity to radiation confirmed
by in vitro radiosensitivity tests. The
best known example ataxia
teleangiecŁasia (AT) is particularly
interesting while considering the breast
cancer patients radiosensitivity. The
frequency of AT heterozygotes in a
normai population has been estimated
to be 1%. These individuals have an
increased in vitro radiosensitivity of
fibroblasts and also have an increased
risk (approximately 8 times) of
developing breast cancer. Therefore the
frequency of AT gene (connected with
higher radiosensitivity) occurs in breast
cancer patients with a much higher
frequency than that in general
population and it was calculated to
amount to 8-18% (Andersen, 1996,
Norman et al., 1992). These findings
have generated a great interest in
testing of individual radiosensitivity with
the hope that it will make it possible to
modify the radiotherapeutic schedules
according to the results of these tests.
Indeed some studies have shown a
correlation between the in vitro
sensitivity of fibroblasts and clinical
normai tissue reaction (Johansen et al.,
1994). On the other hand, lack of a
correlation between radiosensitivity of
various celi types has been reported.
Also, in breast cancer patients there
was no significant correlation between
the severity of radiation changes for twa
different tissues (e.g. teleangiectasia
and subcutaneous fibrosis) in the same
patient (sa cal/ed intra-patients
variability) (Bentzen et al., 1993). At
present, it seems unlikely that a single
and simple assay (e.g. micronucleus
assay on peripheral blood Iymphocytes)
could be used as a reliable predictor for
late radiation effect in several tissues.
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Radiation injury to the heart may have
different presentations including: early
(exudative) and late (constrictive) pericarditis,
pancarditis, valvular and conduction defects, a
coronary arteries disease and myocardial
infarction. Although the heart was initially
considered radioresistant, radiation heart injury
was found to be a clinically important problem,
especially in long term survivors after
radiotherapy for Hodgkin's disease (Levitt,
1995).
In breast cancer patients, particularly in those
with left sided tumours, the heart may receive a
significant dose depending on the radiotherapy
technique used. In several reports increased
non-breast cancer mortality was found in
irradiated patients in comparision with those
treated by mastectomy alone (Haybittle et al.,
1989; Host et al., 1896, Jones and Ribeiro,
1989; Rutqvist and Johansson, 1990).
This problem was addressed in the
retrospective analysis performed in the group of
1885 patients with breast cancer treated at the
Centre of Oncology in- Kraków between 1952-
80. Surgery alone was used in 1068 patients,
and 817 patients were irradiated
postoperatively.
The orthovoltage technique was used in 650
patients, who received doses of 36-40 Gy in 20
fractions; the remaining 167 patients were
treated with 60 Co technique with a dose of 50
Gy in 25 fractions. The treatment volume
included the chest wall and regional Iymph
nodes in all patients. Adjuvant systemie therapy
was not applied. The cumulated incidence af
non-breast cancer deaths was calculated using
life tables method (Table 7).
Treatment Numberof Risk of non-breast Chi'
method patients cancer death
10 years 20 years
Surgery 1068 6.3% 16.4% 1.520
alone N.S.
Surgery+ 817 4.7% 9.9%
RT
Table 7. Comparison of the risk of non breast cancer
death in patients treated with surgery alone and with
postoperative radiotherapy (RT).
After 10 years, the risk of non-cancer death was
6.3% in patients treated with surgery alone and
4.7% in patients irradiated postoperatively. After
20 years, these rates rase to 16.4 % and 9.9%
30
respectively. The difference however, was not
statistically significant. Thus, aur analysis did not
show any increased risk of nan-breast cancer
mortalityin the irradiated patients. This result
should, however, be treated with caution
because of the retrospective nature of the study.
In fact, patients treated with surgery alone were
slightly but significantly older (mean age 54
years) than those irradiated postoperatively (52
years). It was also not possible to distinguish
cardiac deaths from other non cancer deaths
(Korzeniowski, 1991). More reliable data come
from the analysis of clinical triais. Long term
results of several clinical triais assessing the
value of postoperative radiotherapy
demonstrated a signific;:ant increase in non-
breast cancer deaths in the irradiated groups,
which was due to an excess of cardiac mortality.
The increase in cardiac deaths became
apparent in long term survivors, usually in the
second decade of observation, and was more
pronounced in older (>60 years) patients and in
patients with left sided breast cancer (Haybittle
et al., 1989; Host et al., 1896; Jones and
Ribeiro, 1989; Rutqvist et al., 1992).
Observations fram individual triais were
subsequently confirmed in two metaanalyses
performed by Cizick et. al. (Cuzick et al., 1994;
Cuzick et al., 1987). Data fram metaanalyses
suggest that an increased risk of cardiac death
may be related to radiation quality
(orthovoltage), tataI dose and volume of the
heart irradiated and to the use of high dose per
fraction (Table 8).
Centre RT Dose Number P-value




Manchester 250 KV 35-40 15 0.06
Quadrate
Manchester 250 KV 32.5-42.5 15 0.02
Peripheral
Oslo II 60 Co 50 20 0.07
Heidelberg 60 Co 54 30 0.05
Stockholm 60 Co 45 25 0.28
lelectrons
Table 8. Increased risk of cardiac death in relation to
radiation quality and dose in patients irradiated
postoperatively wilhin randomised triaIs who survived
over 10 years. Modified from J Cuzick et al. (Cuzick et
al., 1994).
A detailed analysis was performed with this
respect in patients treated in the Stockholm trial
and the importance af the radiotherapy
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technique was confirmed. Jncreased cardiac
mortality was found only in patients who
received high doses to a large volume of the
heart (patients with left sided cancer treated with
60 Co tangential beams) (Rutqvist et al., 1992).
Fuller et. al. compared doses given to the heart
and coronary arteries with old orthovoltage and
modern megavoltage techniques and found that
in the megavoltage mode the total dose to the
heart was significantly reduced, but in patients
with the cancer of the left breast the part of the
left ventricle and the left anterior descending
coronary artery may have received relatively
high doses (Fuller et al., 1992).
The radiation induced heart disease is the
most serious complication of postmastectomy
irradiation. With modern radiotherapy
equipment, the use of electron beams, carefuI
individual treatment planning, the irradiation of
the myocardium may be avoided. Thus with
appropriate techniques and the use of
conventional fractionation (2 Gy) the risk of




Another possible and important complication
of postoperative radiotherapy in breast cancer
patients is the induction of secondary
malignancies, and, in particular cancer of the
contralateral breast. Breast tissue was shown to
be sensitive to radiation carcinogenesis. The
risk of radiation induced breast cancer is
influenced by dose and age at exposure. The
risk of carcinogenesis increases linearly with the
dose up to 10 Gy, but at the therapeutic range
(45 - 50) it seems to be smali, probably due to
the process of celi inactivation. In relation to
age, the highest risk occurs in females exposed
to radiation in adolescence, with increasing age
the risk declines and seelTJs to be very low for
women over 40 years of age. The dose to the
opposite breast from postoperative radiotherapy
was estimated to be in the range of 1 to 3 Gy,
therefore, it could lead to the induction of
contralateral breast cancer. The risk is difficult to
assess because patients with breast cancer,
even if not irradiated, are at· a higher risk of
developing cancer in contralateral breast with a
relative risk between 2.0 and 4.0 (Harris and
Morrow, 1996).
Other radiation induced tumours which may
develop within tissues irradiated during
postoperative radiotherapy include soft tissue
and bone sarcomas, the cancer of the lung, the
oesophagus skin and the thyroid.
In the study performed at the Kraków Centre of
Oncology in the group of 1885 patients
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(described above) the long term risk of
contralateral breast cancer and malignant
tumours in other sites was assessed (Table 9
and 10). Cumulative incidence of contralateral
breast cancer after 10 years was 4.4% for
patients treated with surgery alone and 2.8% for
the irradiated group; 20-year rates were 6.5%
and 4.1 %, respectively (p<0.05). The risk of
developing a neoplasm in other sites was: 8.6%
after 10 years in the surgical group and 5.4% in
the combined modality group; the respective
rates were 11.4% and 9% (p<0.05). Thus, the
incidence of contralateral breast cancer and
other malignancies appeared to be higher in
patients treated with surgery alone, which may
be explained by the older age of patients in the
surgery alone group.
Localizalion Trealmenl Number Incidence Chi
melhod ot 10 20 p-value
palienls years years
Contralalerai Surgery 1068 4.4% 6.5% 4.93
breasI alane
Surgery + 817 2.8% 4.1% p<0.05
RT
Tumours in Surgery 1068 8.6% 11.4% 4.68
olher siles alane
Surgery + 817 5.4% 9.0% p<0.05
RT
Table 9. Incidence of cancer of contralateral breast
and tumours in other sites in patients treated with
surgery alone and with postoperative readiotherapy
(RT).
Lacalizatian Surgery alane Surgery + RT
Stornach 6 (15.4%) 2(9%)
Colon 3(7.7%) 3 (13.3%)
Lung 2 (5.1%) 1 (4.5%)
Skin 4 (10.3%) 3 (13.6%)
Uterine cervix 4 (10.3%) 3 (13.6%)
Endometrium 6 (15.4%) O
Ovary 2 (5.1%) 2 (9.1%)
Other 12 (30.7%) 8 (36.4%)
Total 39 (100%) 22 (100%)
Table 10. Comparison of localization of secondary
tumours, in patients treated with surgery alone (1068
patients) and with postoperative radiotherapy (817
patients).
There were two cases of lung cancer in patients
treated with surgery alone and one in the
irradiated group. Skin cancer developed in one
patient within the irradiated chest wall. The
distribution of tumours in other sites was, in
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exception of the cancer of endometrium. This
difference, too large to be explained by older
age, prabably appeared by chance. Neither
sarcoma nor leukaemia cases were found in this
material (Korzeniowski 1991).
A number of other studies have also
addressed the risk of secondary neoplasms
after post mastectomy radiotherapy. Boice et al.
studied the incidence of contralateral breast
cancer in a cohort of 41109 patients with breast
cancer diagnosed between 1935-82 (Boice et al.;
1992). In patients who survived for at least 10
years they found a smali, but marginally
significant increase of risk of contralateral breast
cancer (RR=1.33), associated with the usa of
postoperative radiotherapy. This risk was
evident in patients less than 45 years of age
when treated (RR=1.59), but not in older
patients (RR=1.01). On the contrary, a large
study fram Oenmark, which included 56560
patients treated between 1943-78, did not show
any increased risk of contralateral breast cancer
in the irradiated patients (RR=1.04) (Storn et al.;
1992). The data fram the Iiterature suggests that
the risk of radiation induced contralateral breast
cancer, if it exists,is very smalI. Boice et al.
estimated that for younger «45 years) patients
the risk of contralateral breast cancer within 15
years is about 11 %without radiotherapy and
about 12% with radiotherapy. After 30 years, it
was calculated to increase to about 22% and
25% respectively. Thus, especially in young
patients, the dose to the contralateral breast
should be reduced to the possibly lowest levels.
Various technical solutions ot how to minimise
the dose to the contralateral breast have
recently been praposed (Epstein et al., 1996).
Rare but undoubtedly radiation-induced
tumours are sarcomas ot the soft tissue and
bone which develop within the treated area. In a
series from France, 9 of 7620 patients irradiated
for breast cancer developed sarcoma within the
irradiated volume. The mean latency period was
9.5 years and the cumulative incidence was
estimated to be 0.2% after 10 years and 0.43%
after 20 years (Taghian et al., 1991).
Lymphangiosarcoma arising in Iymphoedema ot
the arm is a very rare tumour, and it is not Iike
other sarcomas, a true postirradiation neoplasm,
since it occurs also in patients treated with
surgery alone. However, this complication may
be regarded as a radiation related since
radiotherapy increases the incidence and
severity of the arm oedema.
An increase in the incidence ot lung cancer
was also found in patients irradiated tor breast
cancer. The relative risk for the period of 10
years or longer following treatment was
estimated to be 1.8, which corresponds to
approximately 9 cases of radiotherapy-induced
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lung cancer per year among 10.000 breast
cancer patients whose survival time was over 10
years (Levitt, 1995, Taghian et al., 1991).
Finally, a smali increase in the incidence of
acute nonlymphocytic leukemia in breast cancer
patients treated with radiotherapy was
suggested in one report, but not confirmed in
others (Inskip et al., 1994). This requires further
studies and may be of importance in patients
receiving adjuvant chemotherapy with alkylating
agents, which were also reported to have a
leucemogenic effect.
CONCLUSIONS
Studies on late radiation effects in patients
treated with postmastectomy irradiation have
proved very useful in the understanding of
radiobiological processes. The crucial
importance of dose per fraction, as well as
interactions between radiotherapy and
chemotherapy or surgery in relation to incidence
and severity of radiation sequelae, has been
well documented in clinical materials. The most
significant complication of postoperative
radiotherapy in breast cancerpatients has been
a long term increase in cardiac mortality. As
suggested by recent overviews that increase in
cardiac mortality and, to lesser extent,
secondary malignancies, may possibly offset the
survival advantage tram postoperative
radiotherapy.
The optimisation of radiotherapy techniques.
involving beam energies, field arrangements,
shielding of critical normai tissues and the use ot
conventional fractionation, should in future
greatly diminish radiotherapy related morbidity.
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